FDA Approves Augtyro (repotrectinib) for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2023 Category: Drugs & Pharmacology Source Type: news
Non-Small Cell Lung Cancer Highlights From ESMO 2023 Non-Small Cell Lung Cancer Highlights From ESMO 2023
Key studies on non –small cell lung cancer presented at ESMO 2023 include strong practice-changing results from the PAPILLON, LIBRETTO, and MARIPOSA trials, as discussed by Dr Enriqueta Felipe.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 14, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news
Rate of New Lung Cancer Cases Has Decreased Over Last Five Years
TUESDAY, Nov. 14, 2023 -- The rate of new lung cancer cases has decreased and survival has improved over the last five years, according to the State of Lung Cancer 2023 report published Nov. 14 by the American Lung Association.
In the report,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 14, 2023 Category: Pharmaceuticals Source Type: news
Americans More Likely To Survive Lung Cancer Than Ever Before —But Black And Latino Patients Still Disproportionately Dying
More Americans are surviving lung cancer than ever before, a new State of Lung Cancer report says, but Black and Latino people are still significantly less likely to live for five years after diagnosis than their white peers. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 14, 2023 Category: Pharmaceuticals Authors: Mary Whitfill Roeloffs, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news topline Source Type: news
Lung cancer survival rates have risen, but data show racial inequality
The report highlights the need for better messaging about screening for lung cancer, which is still the nation’s leading cause of cancer-related deaths. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - November 14, 2023 Category: Consumer Health News Authors: Sabrina Malhi Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Investor Update - November 14, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Media News - November 14, 2023 Category: Pharmaceuticals Source Type: news
Mayo Clinic expert on the importance of lung cancer screening
Screening for lung cancer can save lives, and there's an urgent need for more screening of people of color. That's one of the takeaways from the newly released "State of Lung Cancer" report from the American Lung Association. "Lung cancer is the largest (cancer) killer of adult men and women worldwide. Many of the reasons for that is it's so late in its stage, often, when it's diagnosed," says Dr. Janani Reisenauer, a thoracic surgeon… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 14, 2023 Category: Databases & Libraries Source Type: news
Why I'm Sticking With the USPSTF on Lung Cancer Screening Why I'm Sticking With the USPSTF on Lung Cancer Screening
ACS recommends continuing lung cancer screening to age 80, regardless of how long ago patients quit smoking. Dr Kenny Lin explains why he ' s following the USPSTF ' s recommendations for now.Medscape Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2023 Category: Consumer Health News Tags: Family Medicine/Primary Care Commentary Source Type: news
Road to RSNA 2023: CT
Photon-counting CT (PCCT) has dominated discussion for the last number of RSNA meetings, and this year will be no exception. Expect to hear PCCT research findings about how the technology can increase image quality and lower radiation dose in pulmonary angiography for the diagnosis of pulmonary embolism; how it appears to boost the contrast-to-noise ratio of vascular structures on chest CT; and what it has to offer in the musculoskeletal arena.
Meeting attendees will also get the scoop on the role CT radiomics can play in clinical care, particularly helping clinicians determine the best treatment for patients sufferi...
Source: AuntMinnie.com Headlines - November 13, 2023 Category: Radiology Authors: Kate Madden Yee Tags: 2023 2023 CT Preview Source Type: news
CT-based deep learning radiomics may help determine NSCLC treatment
Thursday, November 30 | 11:10 a.m.-11:20 a.m. | R4-SSCH10-2 | Room S405 A CT-based deep-learning radiomics biomarker appears to characterize the level of expression of programmed cell death ligand 1 (PD-L1) in non-small cell lung cancers (NSCLCs), according to study results that will be presented Thursday morning.The findings could help clinicians set treatment for lung cancer patients, since tumors that express 50% or greater levels of PD-L1 tend to respond well to immunotherapy, wrote a team led by Jingshan Gong, MD, of Shenzhen Second People's Hospital in China.The study included 259 patients with pathology-confirmed ...
Source: AuntMinnie.com Headlines - November 13, 2023 Category: Radiology Authors: Kate Madden Yee Tags: 2023 CT Preview Source Type: news
TLS in Tumors May Predict Immunotherapy Benefit in NSCLC TLS in Tumors May Predict Immunotherapy Benefit in NSCLC
New data indicate that tertiary lymphoid structures could predict which patients with advanced non-small cell lung cancer will benefit most from immunotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 10, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 -- (Healthcare Sales & Marketing Network) -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure, the Comp... Biopharmaceuticals, Oncology, Regulatory Mirati Therapeutics, KRAZATI, adagrasib, Non-Small Cell Lung Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 10, 2023 Category: Pharmaceuticals Source Type: news
Lung cancer pill that HALVES patients' risk of death is hailed 'earth-shattering' by specialists
Osimertinib can slash the risk of the disease returning by more than 70 per cent, and cuts deaths in half. (Source: the Mail online | Health)
Source: the Mail online | Health - November 9, 2023 Category: Consumer Health News Source Type: news
2023 Guidelines Update Eligibility for Lung Cancer Screening
THURSDAY, Nov. 9, 2023 -- In a guideline update issued by the American Cancer Society and published online Nov. 1 in CA: A Cancer Journal for Clinicians, the authors recommend increasing eligibility for lung cancer screening (LCS).Andrew M.D. Wolf,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 9, 2023 Category: Pharmaceuticals Source Type: news
